Cochrane · systematic review · CD013751
Hypoxia‐inducible factor stabilisers for the anaemia of chronic kidney disease
Natale, P, Palmer, SC, Jaure, A, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 4 · 28.6%Low 4 · 28.6%Moderate 3 · 21.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Hypoxia‐inducible factor (HIF) stabilisers versus placebo for people with chronic kidney disease (CKD)
Population: people with CKD (including HD and PD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiovascular death Median Hypoxia‐inducible factor (HIF) stabilisers vs placebo | RR 3.68 [0.19, 70.21] | 10 studies · 1114 participants | Very low Downgraded: risk of bias |
Fatigue Hypoxia‐inducible factor (HIF) stabilisers vs placebo | no estimate extracted | NR | No studies |
Life participation Hypoxia‐inducible factor (HIF) stabilisers vs placebo | no estimate extracted | NR | No studies |
Nonfatal myocardial infarction Median Hypoxia‐inducible factor (HIF) stabilisers vs placebo | RR 1.29 [0.31, 5.36] | 3 studies · 822 participants | Very low Downgraded: risk of bias |
Nonfatal stroke Median Hypoxia‐inducible factor (HIF) stabilisers vs placebo | no estimate extracted | 2 studies · 228 participants | Very low Downgraded: risk of bias |
Proportion of patients requiring blood transfusion Median Hypoxia‐inducible factor (HIF) stabilisers vs placebo | RR 0.51 [0.44, 0.6] | 8 studies · 4329 participants | Moderate Downgraded: risk of bias |
Proportion reaching target haemoglobin Median Hypoxia‐inducible factor (HIF) stabilisers vs placebo | RR 8.36 [6.42, 10.89] | 10 studies · 5102 participants | Moderate Downgraded: risk of bias |
Hypoxia‐inducible factor (HIF) stabilisers versus erythropoiesis‐stimulating agent (ESA) for people with chronic kidney disease (CKD)
Population: people with CKD (including HD and PD)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Cardiovascular death Median Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | RR 1.05 [0.88, 1.26] | 17 studies · 10340 participants | Low Downgraded: risk of bias |
Fatigue Median Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | RR 0.8 [0.56, 1.16] | 2 studies · 3471 participants | Very low Downgraded: risk of bias |
Life participation Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | no estimate extracted | NR | No studies |
Nonfatal myocardial infarction Median Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | RR 0.91 [0.76, 1.1] | 7 studies · 7765 participants | Low Downgraded: risk of bias |
Nonfatal stroke Median Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | RR 1.06 [0.71, 1.56] | 5 studies · 7285 participants | Low Downgraded: risk of bias |
Proportion of patients requiring blood transfusion Median Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | RR 0.87 [0.76, 1] | 11 studies · 10786 participants | Moderate Downgraded: risk of bias |
Proportion reaching target haemoglobin Median Hypoxia‐inducible factor (HIF) stabilisers vs erythropoiesis‐stimulating agent (ESA) | RR 1 [0.93, 1.07] | 14 studies · 4601 participants | Low Downgraded: risk of bias |